Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

IMRIS Inc receives Australian regulatory clearance for intraoperative CT solution


Wednesday, 26 Feb 2014 08:00am EST 

IMRIS Inc:Obtained Therapeutic Goods Administration (TGA) regulatory listing for VISIUS iCT, the first and only ceiling-mounted intraoperative computed tomography, allowing for sales and marketing in Australia.Received U.S. Food and Drug Administration (FDA) 510(k) and CE mark clearance for VISIUS iCT in July 2013. 

Company Quote

0.52
0.06 +13.04%
24 Dec 2014